Proteomics Market Analysis
The global proteomics market size was valued at USD 30.61 billion in 2023 and is projected to reach USD 96.35 billion by 2032, expanding at a compound annual growth rate (CAGR) of 13.61% during the forecast period from 2024 to 2032. This significant market growth is propelled by rapid advancements in analytical technologies, heightened focus on personalized medicine, and the growing use of proteomics in drug discovery and clinical diagnostics.
Spectrometry Leads Technology Growth with Increasing Role in Biomarker Discovery
Among the technologies assessed, the spectrometry segment led the market in 2023 and is expected to maintain its dominance with an anticipated CAGR of 15.10% through 2032. Spectrometry plays a pivotal role in protein identification, characterization, and the detection of post-translational modifications. Recent advancements in mass spectrometry—including enhanced resolution, accelerated processing speeds, and automation—have elevated the method’s precision and throughput, making it indispensable in modern proteomics research.
Integration with bioinformatics tools has extended the utility of spectrometry across drug development, biomarker identification, and personalized medicine, strengthening its market leadership. Companies like Thermo Fisher Scientific and Waters Corporation continue to invest in next-generation spectrometry systems, supporting this upward trend.
Get a Free Sample Report of Proteomics Market @ https://www.snsinsider.com/sample-request/3950
Next-Generation Sequencing (NGS) Poised for Rapid Adoption
The next-generation sequencing (NGS) segment is set for accelerated growth during the forecast period, largely due to declining sequencing costs and enhanced accessibility across clinical and research applications. NGS is now widely adopted in fields such as oncology, genetic disease diagnostics, and individualized treatment plans.
A key industry development includes the February 2024 strategic alliance between Pixelgen Technologies and BioStream Co. Ltd., aimed at distributing spatial proteomics tools for single-cell analysis using NGS. This collaboration reflects how NGS technologies are being repurposed for high-resolution proteomic profiling, enabling scientists to study protein expression at unprecedented depths.
Drug Discovery Dominates Applications with More Than Half the Market Share
In 2023, the drug discovery application segment accounted for 54.76% of the global proteomics market revenue. The stronghold of this segment is driven by innovations in structure-based drug design, increased demand for personalized therapeutics, and rising investment in biopharma R&D.
Proteomics enables early-phase assessment of drug efficacy and toxicity, thereby reducing costs and improving outcomes in drug development pipelines. By identifying disease-specific protein targets, pharmaceutical companies can better tailor treatment strategies and improve patient outcomes, creating a direct link between proteomics and success in precision medicine.
Clinical Diagnostics to Register Fastest Growth
While drug discovery currently dominates, the clinical diagnostics segment is expected to register the highest CAGR in the coming years. The segment’s growth is supported by increasing use of proteomics in biomarker discovery, aiding in the early diagnosis of diseases and risk assessment at an individual level.
Diagnostic applications of proteomics tools allow for tumor classification, disease prognosis, and treatment response prediction, especially in oncology and neurodegenerative conditions. The increased focus on protein expression profiling in clinical settings will likely accelerate this growth trend.
North America Leads, Asia Pacific Emerges as a High-Growth Market
In terms of regional dynamics, North America led the global proteomics market in 2023, capturing over 46.87% of the total revenue share. This leadership is attributed to advanced healthcare infrastructure, robust investments in precision medicine, and continuous innovation in mass spectrometry and bioanalytical tools. The U.S. market benefits from a dense concentration of biotechnology firms, world-class research institutions, and proactive regulatory frameworks that support innovation in life sciences.
On the other hand, the Asia Pacific proteomics market is forecasted to experience the highest growth, with a projected CAGR of 16.47% from 2024 to 2032. The region is witnessing increased demand due to rising chronic disease incidence, government-backed R&D funding, and outsourcing of proteomics services to countries like India, China, and Japan. Japan’s strong position is reinforced by ongoing drug discovery programs and widespread adoption of personalized medicine.
Recent Industry Developments Reinforce Innovation Pipeline
Key market participants are continuously introducing cutting-edge technologies to stay competitive. For instance:
Agilent Technologies launched the ExD Cell in July 2024, enhancing protein characterization when paired with its 6545XT AdvanceBio LC/Q-TOF system.
At the 72nd ASMS Conference in June 2024, Agilent unveiled new mass spectrometry advancements aimed at improving protein and peptide analysis workflows.
Strategic partnerships, such as the Pixelgen-BioStream collaboration, highlight industry emphasis on spatial proteomics and single-cell applications.
These developments point to a clear industry trend: the convergence of automation, miniaturization, and computational biology to improve efficiency and discovery rates in proteomics.
Leading Market Participants in the Proteomics Ecosystem
Prominent players shaping the proteomics market include:
Thermo Fisher Scientific – Orbitrap Fusion Lumos
Agilent Technologies – SureScan Dx Microarray System
Waters Corporation – Xevo TQ-S Micro Mass Spectrometer
PerkinElmer – AxION iQT Mass Spectrometer
Bio-Rad Laboratories – ChemiDoc Imaging System
Bruker Corporation, GE Healthcare Life Sciences, Qiagen, Illumina, Sartorius AG, Roche Diagnostics, Sysmex Corporation, and others.
These companies are focused on delivering high-throughput and high-sensitivity proteomic tools to meet the evolving demands of academic research, clinical diagnostics, and pharmaceutical development.
Buy a Single-User PDF of Proteomics Market Analysis & Outlook Report 2024-3950 @ https://www.snsinsider.com/checkout/3950
Conclusion
The global proteomics market is witnessing a transformational phase driven by technological breakthroughs, strategic collaborations, and expanding clinical applications. From accelerating drug discovery pipelines to enabling early diagnosis through personalized biomarkers, proteomics stands at the forefront of biomedical innovation.
As spectrometry and NGS technologies evolve and regional markets like Asia Pacific gain momentum, stakeholders across healthcare, biotech, and diagnostics must align their strategies to capitalize on the surging demand and unlock the full potential of the proteomics revolution.
Read Our Other Report
About Us:
SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company’s aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world.
Contact Us:
Jagney Dave – Vice President of Client Engagement
Phone: +1-315 636 4242 (US) | +44- 20 3290 5010 (UK)
Email: [email protected]
